Edition:
India

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

7.58USD
20 Oct 2020
Change (% chg)

$-0.37 (-4.65%)
Prev Close
$7.95
Open
$7.95
Day's High
$7.95
Day's Low
$7.34
Volume
185,629
Avg. Vol
258,518
52-wk High
$8.68
52-wk Low
$1.49

Select another date:

Tue, Jul 7 2020

BRIEF-Aldeyra Therapeutics Announces New Drug Application Development Plans For Dry Eye Disease

* ALDEYRA THERAPEUTICS ANNOUNCES NEW DRUG APPLICATION (NDA) DEVELOPMENT PLANS FOR DRY EYE DISEASE

BRIEF-Aldeyra Receives Orphan Medicinal Product Designation From European Commission For ADX-2191 Retinal Disease Program

* ALDEYRA THERAPEUTICS RECEIVES ORPHAN MEDICINAL PRODUCT DESIGNATION FROM EUROPEAN COMMISSION FOR ADX-2191 RETINAL DISEASE PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics Reaches Agreement With FDA To Use RASP as An Objective Sign For The Treatment Of Dry Eye Disease

* ALDEYRA THERAPEUTICS REACHES AGREEMENT WITH THE US FOOD AND DRUG ADMINISTRATION FOR THE USE OF RASP AS AN OBJECTIVE SIGN FOR THE TREATMENT OF DRY EYE DISEASE

BRIEF-Aldeyra Therapeutics To Test ADX-1612 Against COVID-19

* ALDEYRA THERAPEUTICS TO ADVANCE ADX-1612, AN INVESTIGATIONAL NEW HSP90 INHIBITOR WITH POTENTIAL NANOMOLAR POTENCY AGAINST SARS-COV-2, TO CLINICAL TESTING FOR COVID-19; ADX-629 ACCEPTED FOR BARDA CORONAWATCH MEETING

BRIEF-Aldeyra Therapeutics Q1 Loss Per Share $0.34

* ALDEYRA THERAPEUTICS REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS AND ANNOUNCES NEW CLINICAL PROGRAMS

Select another date: